FDA accepts NDA for ulipristal from Allergan for uterine bleeding

Allergan plc (NYSE:AGN) said FDA accepted for review an NDA for ulipristal acetate (Esmya - EU, Fibristal - Canada, Ella, ellaOne, PGL4001) to treat abnormal uterine bleeding in women with uterine fibroids. The company expects a 1H18 PDUFA date...